Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DK6BL5
|
|||
| Drug Name |
Bepranemab
|
|||
| Synonyms |
RG6416
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
Roche/Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Microtubule-associated protein tau (MAPT) | Target Info | Inhibitor | [2] |
| Microtubule-associated protein tau (MAPT) | Target Info | . | [2] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Alzheimer's disease | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| EGFR1 Signaling Pathway | ||||
| Pathway Interaction Database | LPA receptor mediated events | |||
| Reelin signaling pathway | ||||
| Reactome | Caspase-mediated cleavage of cytoskeletal proteins | |||
| WikiPathways | Notch Signaling Pathway | |||
| IL-2 Signaling Pathway | ||||
| MAPK Signaling Pathway | ||||
| Copper homeostasis | ||||
| Kit receptor signaling pathway | ||||
| BDNF signaling pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Alzheimers Disease | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| Apoptotic execution phase | ||||
| IL-5 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04867616) A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period. U.S.National Institutes of Health. | |||
| REF 2 | Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.